Finanzen von Ping An Biomedical Co Ltd (PASW)PASWPing An Biomedical Co Ltd

Evaluating the bottom line, Ping An Biomedical Co Ltd maintains a gross margin of 7.54%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 5.60%, while the net margin is 50.30%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively PASW converts its operational activities into shareholder value.

In the context of the broader market, PASW competes directly with industry leaders such as JL and TLIH. With a market capitalization of $16.77M, it holds a significant position in the sector. When comparing efficiency, PASW's gross margin of 7.54% stands against JL's 31.19% and TLIH's 24.04%. Such benchmarking helps identify whether Ping An Biomedical Co Ltd is trading at a premium or discount relative to its financial performance.

The financial performance shows a recent improvement in gross margin, which increased to 7.54% in Q2 2026, but the company has a history of negative earnings per share (EPS) with a Q2 2025 EPS of -0.24 and a Q4 2025 EPS of -0.69. The current ratio is healthy at 2.54, indicating good short-term financial health.